BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009;44 Suppl 19:119-21. [PMID: 19148805 DOI: 10.1007/s00535-008-2244-z] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S34-43. [PMID: 21739567 DOI: 10.1002/lt.22369] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
2 Takami H, Kanda M, Oya H, Hibino S, Sugimoto H, Suenaga M, Yamada S, Nishikawa Y, Asai M, Fujii T. Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol. 2013;108:557-562. [PMID: 24068544 DOI: 10.1002/jso.23440] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
3 Kudo M. Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. Liver Cancer 2012;1:141-3. [PMID: 24159578 DOI: 10.1159/000342749] [Cited by in Crossref: 26] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
4 Hanazaki K, Ichikawa K, Munekage M, Kitagawa H, Dabanaka K, Namikawa T. Effect of Daikenchuto (TJ-100) on abdominal bloating in hepatectomized patients. World J Gastrointest Surg 2013; 5(4): 115-122 [PMID: 23671738 DOI: 10.4240/wjgs.v5.i4.115] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
5 Toyoda H, Kumada T, Tada T, Ito T, Maeda A, Kaneoka Y, Kagebayashi C, Satomura S. Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy. Cancer Med. 2014;3:643-651. [PMID: 24591342 DOI: 10.1002/cam4.218] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Journal of Hepatology 2009;51:315-21. [DOI: 10.1016/j.jhep.2009.04.011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
7 Toyoda H, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J. Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. Hepatol Commun 2021;5:1290-9. [PMID: 34278176 DOI: 10.1002/hep4.1716] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Tamura S, Sugawara Y, Kokudo N. Section 4. Further Expanding the Criteria for HCC in Living Donor Liver Transplantation: The Tokyo University Experience. Transplantation 2014;97:S17-20. [DOI: 10.1097/01.tp.0000446268.26771.59] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
9 Dormandy TL, Munro JG. Oxyhaemoglobin without oxygen. Nature. 1965;206:410-411. [PMID: 4284287 DOI: 10.1016/j.jceh.2014.05.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 0.7] [Reference Citation Analysis]
10 Toyoda H, Tada T, Tsuji K, Hiraoka A, Tachi Y, Itobayashi E, Takaguchi K, Senoh T, Takizawa D, Ishikawa T, Kumada T. Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan: Outcomes of HCC after SVR. Hepatol Res 2016;46:734-42. [DOI: 10.1111/hepr.12613] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kora S, Urakawa H, Mitsufuji T, Osame A, Higashihara H, Yoshimitsu K. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience. Cardiovasc Intervent Radiol. 2013;36:1023-1029. [PMID: 23238851 DOI: 10.1007/s00270-012-0537-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
12 Tada T, Kumada T, Toyoda H, Ito T, Sone Y, Kaneoka Y, Maeda A, Okuda S, Otobe K, Takahashi K. Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma. Ultrasound in Medicine & Biology 2015;41:3070-8. [DOI: 10.1016/j.ultrasmedbio.2015.07.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
13 Takada K, Toyoda H, Tada T, Ito T, Hasegawa R, Gotoh T, Ichikawa H, Sone Y, Kumada T. Accurate and rapid identification of feeding arteries with multidetector-row angiography-assisted computed tomography for transarterial chemoembolization for hepatocellular carcinoma. J Gastroenterol 2015;50:1190-6. [DOI: 10.1007/s00535-015-1065-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Bridges JF, Joy SM, Blauvelt BM, Yan W, Marsteller JA. An international comparison of stakeholder motivation to implement liver cancer control. Health Policy Plan 2015;30:645-55. [PMID: 24974105 DOI: 10.1093/heapol/czu044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
15 Kim DY, Kim HJ, Jeong SE, Kim SG, Kim HJ, Sinn DH, Lee YJ, Jeong WK, Choi KS, Heo N, Kim DJ, Kim YS, Kim YB, Kim YJ, Kim H, Park M, Lee CW, Tak WY, Chung JH, Kim SY, Kim Y, Lee W, Kim HS. The Korean guideline for hepatocellular carcinoma surveillance. J Korean Med Assoc 2015;58:385. [DOI: 10.5124/jkma.2015.58.5.385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
16 Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver transplantation for small hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:391-8. [PMID: 27826553 DOI: 10.21037/hbsn.2016.05.03] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
17 Shao Y, Liang P, Wu Y, Huang C, Huang K, Cheng JC, Hsu C, Hsu C, Cheng A, Lin Z. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy. Liver Int 2013;33:1413-9. [DOI: 10.1111/liv.12207] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
18 Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, Otsuji E. Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World J Surg. 2012;36:136-143. [PMID: 22051887 DOI: 10.1007/s00268-011-1317-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
19 Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Kaneoka Y, Maeda A. Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol. 2012;57:1251-1257. [PMID: 22824818 DOI: 10.1016/j.jhep.2012.07.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
20 Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T, Tsutsumi M. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer. 2014;5:221-230. [PMID: 24665346 DOI: 10.7150/jca.7691] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
21 Toyoda H, Kumada T, Tada T, Sone Y, Maeda A, Kaneoka Y. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC. Hepatol Int. 2015;9:84-92. [PMID: 25788383 DOI: 10.1007/s12072-014-9553-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
22 Ikemoto T, Shimada M, Yamada S. Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation. Hepatol Res. 2017;47:23-30. [PMID: 26990590 DOI: 10.1111/hepr.12705] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
23 Ishikawa T. Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(37): 6127-6130 [PMID: 24115808 DOI: 10.3748/wjg.v19.i37.6127] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
24 Nanashima A, Tobinaga S, Masuda J, Miyaaki H, Taura N, Takeshita H, Hidaka S, Sawai T, Nakao K, Nagayasu T. Selecting treatment for hepatocellular carcinoma based on the results of hepatic resection and local ablation therapy. J Surg Oncol 2010;101:481-5. [PMID: 20191611 DOI: 10.1002/jso.21523] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
25 Ochiai T, Ishii H, Toma A, Ishimoto T, Yamamoto Y, Morimura R, Ikoma H, Otsuji E. Modified high dorsal procedure for performing isolated anatomic total caudate lobectomy (with video). World J Surg Oncol 2016;14:132. [PMID: 27129389 DOI: 10.1186/s12957-016-0896-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
26 Kamiyama T, Orimo T, Wakayama K, Shimada S, Nagatsu A, Yokoo H, Kamachi H, Yamashita K, Shimamura T, Taketomi A. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification. World J Surg Oncol 2017;15:156. [PMID: 28830473 DOI: 10.1186/s12957-017-1229-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
27 Lim K, Chow PK, Allen JC, Chia G, Lim M, Cheow P, Chung AY, Ooi LL, Tan S. Microvascular Invasion Is a Better Predictor of Tumor Recurrence and Overall Survival Following Surgical Resection for Hepatocellular Carcinoma Compared to the Milan Criteria. Annals of Surgery 2011;254:108-13. [DOI: 10.1097/sla.0b013e31821ad884] [Cited by in Crossref: 219] [Cited by in F6Publishing: 118] [Article Influence: 19.9] [Reference Citation Analysis]
28 Zhong JH, Wu FX, Li H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol 2014;35:8355-8. [PMID: 25195949 DOI: 10.1007/s13277-014-2571-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
29 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Itobayashi E, Nouso K, Kariyama K, Ishikawa T, Hirooka M, Hiasa Y. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. Cancer Sci. 2017;108:1414-1420. [PMID: 28406546 DOI: 10.1111/cas.13257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
30 Shen Y, Hsu C, Cheng A. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010;45:794-807. [DOI: 10.1007/s00535-010-0270-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
31 Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015;45. [PMID: 25625806 DOI: 10.1111/hepr.12464] [Cited by in Crossref: 203] [Cited by in F6Publishing: 220] [Article Influence: 29.0] [Reference Citation Analysis]
32 Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Kawaratani H, Tsujimoto T, Fukui H. Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. Oncol Lett. 2011;2:69-73. [PMID: 22870131 DOI: 10.3892/ol.2010.196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Lin CL, Kao JH. Optimal management of hepatocellular carcinoma: challenges and opportunities. J Gastroenterol Hepatol 2010;25:1336-8. [PMID: 20659219 DOI: 10.1111/j.1440-1746.2010.06373.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
34 Bridges JF, Gallego G, Blauvelt BM. Controlling liver cancer internationally: A qualitative study of clinicians' perceptions of current public policy needs. Health Res Policy Syst 2011;9:32. [PMID: 21798002 DOI: 10.1186/1478-4505-9-32] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
35 Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 2012;32:1053-1063. [PMID: 22432445 DOI: 10.1111/j.1478-3231.2012.02792.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
36 Berman K, Tandra S, Vuppalanchi R, Ghabril M, Sandrasegaran K, Nguyen J, Caffrey H, Liangpunsakul S, Lumeng L, Kwo P. Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol. 2011;106:899-906. [PMID: 21179013 DOI: 10.1038/ajg.2010.477] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
37 Lim DH, Lee H, Park HC, Lee JA, Kim SW, Yoo BC, Koh KC, Lee JH, Choi MS, Gwak GY. The efficacy of high-dose 3-dimensional conformal radiation therapy in patients with small hepatocellular carcinoma not eligible for other local modalities. Am J Clin Oncol. 2013;36:162-166. [PMID: 22391433 DOI: 10.1097/coc.0b013e3182438dae] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
38 Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Korenaga M, Mizokami M, Narimatsu H. Serum WFA + -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int 2016;36:293-301. [DOI: 10.1111/liv.12907] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
39 Sorin Y, Ikeda K, Kawamura Y, Fujiyama S, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study. Liver Cancer 2018;7:323-34. [PMID: 30488022 DOI: 10.1159/000487311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
40 Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16(4): 418-424 [PMID: 20101765 DOI: 10.3748/wjg.v16.i4.418] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 110] [Article Influence: 9.3] [Reference Citation Analysis]
41 Obi S, Sato S, Kawai T. Current Status of Hepatic Arterial Infusion Chemotherapy. Liver Cancer. 2015;4:188-199. [PMID: 26674592 DOI: 10.1159/000367746] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
42 Kora S, Urakawa H, Mitsufuji T, Osame A, Higashihara H, Ohki T, Yoshimitsu K. Warming effect on miriplatin-lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study. Hepatol Res 2013;43:1100-4. [PMID: 23347354 DOI: 10.1111/hepr.12050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014;3:108-118. [PMID: 24945001 DOI: 10.1159/000343866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
44 Nanashima A, Taura N, Abo T, Ichikawa T, Sakamoto I, Nagayasu T, Nakao K. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci. 2011;56:3086-3100. [PMID: 21706206 DOI: 10.1007/s10620-011-1796-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
45 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 47] [Article Influence: 11.7] [Reference Citation Analysis]
46 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
47 Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, Satomura S. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein & lt; 20 ng/mL. Cancer Sci. 2011;102:1025-1031. [PMID: 21244578 DOI: 10.1111/j.1349-7006.2011.01875.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 5.7] [Reference Citation Analysis]
48 Toyoda H, Kumada T, Tada T, Yama T, Mizuno K, Sone Y, Maeda A, Kaneoka Y, Akita T, Tanaka J. Differences in the impact of prognostic factors for hepatocellular carcinoma over time. Cancer Sci 2017;108:2438-44. [PMID: 28945309 DOI: 10.1111/cas.13406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
49 Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31-39. [PMID: 24159594 DOI: 10.1159/000346220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
50 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
51 Chow PK. Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria? J Gastroenterol Hepatol. 2012;27:452-457. [PMID: 22142283 DOI: 10.1111/j.1440-1746.2011.07034.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
52 Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon 2012;12:e6122. [PMID: 23162601 DOI: 10.5812/hepatmon.6122] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
53 Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Bang HI. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e5811. [PMID: 28296720 DOI: 10.1097/md.0000000000005811] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
54 Hirai T, Shinoda Y, Tateishi R, Asaoka Y, Uchino K, Wake T, Kobayashi H, Ikegami M, Sawada R, Haga N, Koike K, Tanaka S. Early detection of bone metastases of hepatocellular carcinoma reduces bone fracture and paralysis. Japanese Journal of Clinical Oncology 2019;49:529-36. [DOI: 10.1093/jjco/hyz028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
55 Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-68. [PMID: 26280007 DOI: 10.1159/000343875] [Cited by in Crossref: 274] [Cited by in F6Publishing: 272] [Article Influence: 39.1] [Reference Citation Analysis]
56 Kim YI, Park HC, Lim DH, Park HJ, Kang SW, Park SY, Kim JS, Han Y, Paik SW. Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma. Radiat Oncol J 2012;30:189-96. [PMID: 23346538 DOI: 10.3857/roj.2012.30.4.189] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
57 Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Ito T. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015;30:1183-1189. [PMID: 25678094 DOI: 10.1111/jgh.12915] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 9.7] [Reference Citation Analysis]
58 Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M; Liver Cancer Study Group of Japan. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg. 2011;98:552-557. [PMID: 21267990 DOI: 10.1002/bjs.7393] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
59 Kaida T, Nitta H, Kitano Y, Yamamura K, Arima K, Higashi T, Taki K, Nakagawa S, Okabe H, Hayashi H, Imai K, Hashimoto D, Yamashita YI, Chikamoto A, Ishiko T, Beppu T, Baba H. Preoperative platelet-to-lymphocyte ratio can predict recurrence beyond the Milan criteria after hepatectomy for patients with hepatocellular carcinoma. Hepatol Res 2017;47:991-9. [PMID: 28000365 DOI: 10.1111/hepr.12835] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
60 Tamura S, Sugawara Y, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. Oncology. 2011;81 Suppl 1:111-115. [PMID: 22212944 DOI: 10.1159/000333270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
61 Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A. A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. Surgery 2015;157:699-707. [DOI: 10.1016/j.surg.2014.10.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
62 Toyoda H, Hiraoka A, Olivares J, Al-Jarrah T, Devlin P, Kaneoka Y, Maeda A, Yopp AC, Parikh ND, Singal AG. Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31491-9. [PMID: 33295281 DOI: 10.1016/j.cgh.2020.10.033] [Reference Citation Analysis]
63 Park H, Park JY. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int. 2013;2013:310427. [PMID: 24455683 DOI: 10.1155/2013/310427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
64 Ho MC, Hasegawa K, Chen XP, Nagano H, Lee YJ, Chau GY, Zhou J, Wang CC, Choi YR, Poon RT, Kokudo N. Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2016;5:245-56. [PMID: 27781197 DOI: 10.1159/000449336] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
65 Bartolini I, Nelli T, Russolillo N, Cucchetti A, Pesi B, Moraldi L, Ferrero A, Ercolani G, Grazi G, Batignani G. Multiple hepatocellular carcinoma: Long-term outcomes following resection beyond actual guidelines. An Italian multicentric retrospective study. Am J Surg 2021;222:599-605. [PMID: 33546852 DOI: 10.1016/j.amjsurg.2021.01.023] [Reference Citation Analysis]
66 De Gasperi A, Mazza E, Prosperi M. Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery? World J Hepatol 2016; 8(7): 355-367 [PMID: 26981173 DOI: 10.4254/wjh.v8.i7.355] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
67 Hass HG, Vogel U, Scheurlen M, Jobst J. Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays. Gut Liver 2018;12:306-15. [PMID: 29271183 DOI: 10.5009/gnl17277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
68 Memeo R, de Blasi V, Cherkaoui Z, Dehlawi A, De' Angelis N, Piardi T, Sommacale D, Marescaux J, Mutter D, Pessaux P. New Approaches in Locoregional Therapies for Hepatocellular Carcinoma. J Gastrointest Cancer 2016;47:239-46. [PMID: 27270711 DOI: 10.1007/s12029-016-9840-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Fang Q, Xie QS, Chen JM, Shan SL, Xie K, Geng XP, Liu FB. Long-term outcomes after hepatectomy of huge hepatocellular carcinoma: A single-center experience in China. Hepatobiliary Pancreat Dis Int 2019;18:532-7. [PMID: 31543313 DOI: 10.1016/j.hbpd.2019.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
70 Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 2011;81 Suppl 1:158-164. [PMID: 22212951 DOI: 10.1159/000333280] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 6.8] [Reference Citation Analysis]
71 Bo J, Beining K, Xiang F, Xinkun W, Yukun L. Discrepancy of contrast-enhanced ultrasonographic pattern with two contrast agents in steatohepatitic subtype hepatocellular carcinoma: A case report. Radiology Case Reports 2022;17:1905-10. [DOI: 10.1016/j.radcr.2022.03.010] [Reference Citation Analysis]
72 Toshikuni N, Shiroeda H, Ozaki K, Matsue Y, Minato T, Nomura T, Hayashi N, Arisawa T, Tsutsumi M. Advanced ultrasonography technologies to assess the effects of radiofrequency ablation on hepatocellular carcinoma. Radiol Oncol 2013;47:224-9. [PMID: 24133386 DOI: 10.2478/raon-2013-0033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
73 Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Sone Y, Kaneoka Y, Maeda A. Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy. J Hepatol. 2013;58:1174-1180. [PMID: 23376360 DOI: 10.1016/j.jhep.2013.01.030] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
74 Wakuta A, Nouso K, Kariyama K, Nishimura M, Kishida M, Wada N, Mizushima T, Higashi T, Tanimoto M. Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis. Oncology 2011;81:39-44. [PMID: 21912196 DOI: 10.1159/000331411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
75 Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, Bae SH, Tak WY. Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology 2011;81 Suppl 1:134-40. [PMID: 22212947 DOI: 10.1159/000333276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
76 Toyoda H, Kumada T, Kaneoka Y, Maeda A. Amino Acid Substitutions in the Hepatitis C Virus Core Region Are Associated With Postoperative Recurrence and Survival of Patients With HCV Genotype 1b-Associated Hepatocellular Carcinoma. Annals of Surgery 2011;254:326-32. [DOI: 10.1097/sla.0b013e3182263b8e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
77 Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016; 8(14): 607-615 [PMID: 27190577 DOI: 10.4254/wjh.v8.i14.607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
78 Hong SK, Lee KW, Hong SY, Suh S, Hong K, Han ES, Lee JM, Choi Y, Yi NJ, Suh KS. Efficacy of Liver Resection for Single Large Hepatocellular Carcinoma in Child-Pugh A Cirrhosis: Analysis of a Nationwide Cancer Registry Database. Front Oncol 2021;11:674603. [PMID: 33996606 DOI: 10.3389/fonc.2021.674603] [Reference Citation Analysis]
79 Simão A, Madaleno J, Silva N, Rodrigues F, Caseiro P, Costa JN, Carvalho A. Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening. BMC Gastroenterol 2015;15:73. [PMID: 26122937 DOI: 10.1186/s12876-015-0307-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
80 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
81 Yang MY, Wu F, Fang F, Yang H, Zhang JF, Chen GD, Yang LY. Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma. BMC Cancer 2021;21:772. [PMID: 34217251 DOI: 10.1186/s12885-021-08491-3] [Reference Citation Analysis]
82 Higashi T, Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Sobue T; Liver Cancer Study Group of Japan. Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatol Res 2011;41:1208-15. [PMID: 21978019 DOI: 10.1111/j.1872-034X.2011.00880.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
83 Yang H, Chen G, Fang F, Liu Z, Hiu Yan Lau S, Zhang J, Lau WY, Yang L. Dickkopf-1: As a Diagnostic and Prognostic Serum Marker for Early Hepatocellular Carcinoma. Int J Biol Markers 2013;28:286-97. [DOI: 10.5301/jbm.5000015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
84 Chen M, Zheng T, Han S, Zhang L, Bai Y, Fang X, Ding SZ, Yang Y. A preliminary study of plasma cyclase-associated protein 2 as a novel biomarker for early stage and alpha-fetoprotein negative hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol. 2015;39:215-221. [PMID: 25312778 DOI: 10.1016/j.clinre.2014.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
85 Toyoda H, Kumada T, Tada T, Sone Y, Fujimori M. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol 2012;23:317-22.e1. [PMID: 22265248 DOI: 10.1016/j.jvir.2011.11.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
86 Nakayama H, Takayama T. Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma. World J Hepatol 2015; 7(2): 261-269 [PMID: 25729481 DOI: 10.4254/wjh.v7.i2.261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]